2m 2m 2m 2m 2m 2m 2m
ACTINIUM PHARMA (ATNM)
NYSE
$1.16-$0.005 (-0.43%)
Price as of Jun 03, 2026 5:42 PM EDT- $39.5MMarket Cap
- -32.16%1-Year Change
- BiotechnologyIndustry
ACTINIUM PHARMA (ATNM)
$1.16-$0.005 (-0.43%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 90,000 N/A | N/A N/A | 81,000 -92.14% | 1.0M -9.97% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 90,000 N/A | 0 -100.00% | 81,000 -92.14% | 1.0M +322.13% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -21.1M -29.69% | -30.0M -22.30% | -38.7M +67.15% | -23.1M +28.31% | |
Depreciation and Amortization Expense | 173,000 -12.18% | 197,000 -75.06% | 790,000 +13.02% | 699,000 +33.40% | |
Total Operating Expenses | 36.3M -13.73% | 42.1M -19.00% | 52.0M +48.01% | 35.1M +34.57% | |
Operating Profit | -36.2M -13.95% | -42.1M -18.87% | -51.9M +52.24% | -34.1M +36.61% | |
Interest Income | 2.4M -39.14% | 3.9M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 2.4M -39.14% | 3.9M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | 2.4M -39.14% | 3.9M +25.02% | 3.1M +185.37% | 1.1M +472.11% | |
Income before Taxes | -36.2M -13.95% | -42.1M -18.87% | -51.9M +52.24% | -34.1M +37.66% | |
Income Taxes | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -33.9M -11.39% | -38.2M -21.66% | -48.8M +47.86% | -33.0M +33.27% | |
Net Income from Continuing Operations Applicable to Common | -33.9M -11.39% | -38.2M -21.66% | -48.8M +47.86% | -33.0M +33.27% | |
Basic EPS and Net Income | -1.09 -14.17% | -1.27 -30.60% | -1.83 +33.58% | -1.37 +14.17% | |
Diluted EPS and Net Income | -1.09 -14.17% | -1.27 -30.60% | -1.83 +33.58% | -1.37 +14.17% | |
Basic Weighted Average Shares | 31.2M +3.74% | 30.1M +13.03% | 26.6M +10.20% | 24.1M +17.37% | |
Diluted Weighted Average Shares | 31.2M +3.74% | 30.1M +13.03% | 26.6M +10.20% | 24.1M +17.37% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 48.0M -34.16% | 72.9M -4.92% | 76.7M -29.60% | 108.9M +39.93% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 48.0M -34.16% | 72.9M -4.92% | 76.7M -29.60% | 108.9M +39.93% | |
Total Current Assets | 49.4M -33.72% | 74.5M -4.80% | 78.3M -29.46% | 110.9M +39.11% | |
Accumulated Depreciation | 1.1M +19.42% | 891,000 +28.39% | 694,000 +42.51% | 487,000 +45.37% | |
Property and Plant and Equipment and Net | 295,000 -18.96% | 364,000 -33.82% | 550,000 -8.94% | 604,000 +77.65% | |
Total Long-Term Assets | 295,000 -18.96% | 364,000 -33.82% | 550,000 -8.94% | 604,000 +77.65% | |
Total Assets | 51.8M -32.67% | 76.9M -5.58% | 81.4M -28.68% | 114.2M +42.05% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 8.0M -21.49% | 10.1M +83.02% | |
Total Current Liabilities | 8.0M -2.20% | 8.1M -4.07% | 8.5M -20.08% | 10.6M +55.38% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 36.0M -0.03% | 36.0M -1.56% | 36.6M N/A | N/A N/A | |
Total Liabilities | 43.9M -0.45% | 44.1M -2.05% | 45.1M -5.54% | 47.7M +597.22% | |
Retained Earnings | -409.7M +9.02% | -375.8M +11.33% | -337.6M +16.91% | -288.8M +12.91% | |
Total Stockholders Equity | 7.8M -76.09% | 32.8M -9.95% | 36.4M -45.28% | 66.5M -9.61% | |
Total Shares Outstanding | 31.2M 0.00% | 31.2M +12.89% | 27.6M +7.63% | 25.7M +15.94% | |
Cash Flow | |||||
Cash from Operating Activities | -24.6M -25.68% | -33.1M -30.13% | -47.3M -647.61% | 8.6M +141.43% | |
Capital Expenditures | 104,000 +845.45% | 11,000 -92.81% | 153,000 -58.20% | 366,000 +175.19% | |
Cash from Investing Activities | -104,000 +845.45% | -11,000 -92.81% | -153,000 -58.20% | -366,000 +175.19% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -217,000 -100.74% | 29.3M +97.18% | 14.9M -35.65% | 23.1M -34.39% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | -40,274.44% N/A | N/A N/A | -64,098.77% +1,835.89% | -3,311.07% +51.73% | |
Return on Assets | -52.67% +9.04% | -48.30% -3.21% | -49.91% +47.06% | -33.94% +0.54% | |
Return on Equity | -166.96% +50.92% | -110.63% +16.55% | -94.92% +101.28% | -47.16% +28.36% | |
Revenue Growth | N/A N/A | N/A N/A | -92.14% +824.60% | -9.96% -101.84% | |
Current Ratio | 6.20 -32.23% | 9.14 -0.76% | 9.21 -11.73% | 10.44 -10.47% | |
Cash Ratio | 6.02 -32.68% | 8.95 -0.88% | 9.03 -11.91% | 10.25 -9.94% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow